Company profile

DR REDDYS LABORATORIES LTD

NYSE:RDYBiotechnology: Pharmaceutical Preparations

Drug pipeline (280)

AssetStageRevenueTrialsStatus
ABIRATERONE ACETATEapproved26approved
Acetaminophenapproved78approved
ACYCLOVIR SODIUMapproved1approved
Albendazoleapproved0
ALLOPURINOLapproved0

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (223)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03599193phase2completed2017-10-042018-04-30Dr. Reddy's Laboratories LimitedA Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
NCT06193187phase1unknown2024-01-012024-03-01Dr. Reddy's Laboratories (Thailand) LimitedA Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
NCT02205320phase1unknown2014-02-012014-08-01Dr. Reddy's Laboratories LimitedA Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers
NCT03340961phase2completed2017-10-012018-11-07Dr. Reddy's Laboratories LimitedA Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
NCT02010333phase2completed2013-04-012014-07-01Dr. Reddy's Laboratories LimitedA Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation

FDA applications (402)

ApplicationTypeApplicantProducts
ANDA 040007ANDADR REDDYS LABORATORIES LTD
ANDA 040461ANDADR REDDYS LABORATORIES SA
ANDA 062988ANDADR REDDYS LABORATORIES LTD
ANDA 062989ANDADR REDDYS LABORATORIES LTD
ANDA 065044ANDADR REDDYS LABORATORIES SA